ArticleMedical oncology (Northwood, London, England)2026
Design and evaluation of an EpCAM-specific peptide-diphtheria toxin fusion (DT-SNFYMPL) for targeted epithelial cancer treatment.
Article in Medical oncology (Northwood, London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Epithelial cell adhesion molecule (EpCAM, CD326) is a transmembrane glycoprotein that plays important roles in both normal epithelial tissues and epithelial malignancies. Its frequent overexpression in several cancers, including pancreatic, colorectal, and prostate carcinomas, has made it an attractive therapeutic target. In this study, we designed and evaluated a novel EpCAM-binding diphtheria toxin fusion construct, DT-SNFYMPL, in which the EpCAM-binding peptide SNFYMPL was fused to a truncated diphtheria toxin. The recombinant construct was cloned, expressed in Escherichia coli BL21 cells, purified, refolded, and characterized in vitro. Structural modeling and validation predicted a stable three-dimensional structure for the designed protein. Binding analysis demonstrated interaction of DT-SNFYMPL with recombinant EpCAM in an ELISA-based assay. Cytotoxicity studies revealed dose- and time-dependent inhibition of MCF-7 and TC-1 cell proliferation, whereas no significant effect was observed in HUVEC cells under the conditions tested. DT-SNFYMPL also reduced the migration of cancer cells in Transwell assays; however, this effect is likely attributable, at least in part, to toxin-mediated cytotoxicity rather than direct inhibition of migratory pathways. Although the findings demonstrate biological activity of the DT-SNFYMPL construct and support its potential as an EpCAM-binding therapeutic candidate, the present study does not establish EpCAM-dependent internalization, receptor-mediated cytotoxicity, or therapeutic selectivity. Further mechanistic and preclinical studies are required to evaluate its mode of action, safety, and therapeutic potential in EpCAM-expressing malignancies.
Indexed as
Identifiers
42484769What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.